OVERVIEW

Oncology Briefings™: Exploring a New Wave of Progress in the Management of Neutropenia is organized by Physicians' Education Resource, LLC (PER).

Release Date: November 27, 2019
Expiration Date: November 27, 2020

Accreditation:
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Activity Overview:
Chemotherapy induced neutropenia (CIN) is a common adverse event associated with cancer treatment. CIN and its associated complications, including febrile neutropenia, can have serious, life-threatening effects on patients. In addition to an increased risk of infection and worsening of disease, CIN can negatively impact cancer therapy outcomes as chemotherapy dose reductions and delays are common management strategies.

This Oncology Briefings™ program will help clinicians acquire the knowledge to meet challenges associated with the management of CIN through a series of audio interviews with Jeffrey Crawford, MD, an expert in neutropenia, who will discuss guideline recommendations, prophylactic strategies, biosimilars, and novel and emerging agents to treat patients with cancer at risk for febrile neutropenia.

Learning Objectives:
Upon successful completion of this educational activity, you should be better prepared to:
• Identify patients with cancer at low-, intermediate-, and high-risk of developing neutropenia, including febrile neutropenia.
• Discuss clinical evidence supporting the use of primary prophylaxis to help prevent and manage febrile neutropenia in patients with cancer.
• Analyze emerging data on novel agents exhibiting anti-neutropenic effects that can be used in the clinical management of neutropenia in patients with cancer.
• Develop effective management plans focused on pretreatment against neutropenia, and reactive approaches to treat patients when neutropenia occurs.

Benefits of Participating:
• Apply insight from a leading expert investigator to clinical scenarios for patients at risk for developing chemotherapy-induced neutropenia
• Implement strategies to manage neutropenia with current agents and recognize emerging agents and novel strategies for reducing neutropenia
• Recognize important caveats to planning management strategies for complex cases
• Hone decision-making skills when considering treatment options for patients undergoing rigorous chemotherapy regimens in daily clinical practice